APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-08-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellpatientschronictransplantcll
  Phrases that lowered it: combinationfemaleeffect ofaminotransferaseinhibitors
• Sponsor's past termination rate: 25% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Blinding: single (lowers risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 18.2% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Drug's FAERS reports before start: 140137 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 33659 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Sponsor's past trials: 4 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 90.7% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 NCT03255096 · started 2017 · scored riskier than 30% of active trials completed
• Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma NCT02956382 · started 2017 · scored riskier than 89% of active trials completed
• Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies NCT01871675 · started 2013 · scored riskier than 72% of active trials completed
• Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. NCT03886649 · started 2019 · scored riskier than 39% of active trials terminated
• Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma NCT00671112 · started 2008 · scored riskier than 59% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.